Clinical Trials Browser

INDUSTRY × mogamulizumab × Lymphoid × Clear all

Mycosis Fungoides

NCT07132567 2025-09-22

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Recruiting

15 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT06285370 2025-09-18

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Phase 4 Active not recruiting

23 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT05455931 2024-09-04

PROSPER

Active not recruiting

73 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

38 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT00888927 2024-04-25

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Phase 1/2 Completed

42 enrolled 13 charts

Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Phase 2 Completed

1 enrolled 5 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Phase 2 Completed

71 enrolled 15 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 2 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04745234 2024-04-25

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Phase 2 Active not recruiting

34 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous

NCT01173887 2017-03-30

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Phase 2 Completed

44 enrolled

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

NCT00920790 2017-03-29

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Phase 2 Completed

28 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell

NCT00355472 2012-10-18

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Phase 1 Completed

16 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Peripheral

Clinical Trials

CurbMF

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

PROSPER

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL